Wuxi Biologics (Cayman) Inc. (2269)

Overview

WuXi Biologics (Cayman) Inc. stands as a pivotal investment holding company, dedicated to offering comprehensive end-to-end solutions and services tailored for the biologics discovery, development, and manufacturing sectors within the expansive biologics industry. This organization maintains a broad geographical footprint, extending its professional reach across the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia, showcasing its global operational capabilities. With its business operations bifurcated into two primary segments: Biologics and XDC, WuXi Biologics endeavours to meet the dynamic needs of its clients through an extensive portfolio of contract research, development, and manufacturing organization platforms. Founded in the year 2014, this company has established its headquarters in Wuxi, China, reflecting its roots and commitment to innovation within the biopharmaceutical sphere.

Products and Services

WuXi Biologics offers a diverse suite of products and services across various stages of biologic discovery, development, and manufacturing:

• WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh: These are core platforms that facilitate biologic discovery from concept to IND (Investigational New Drug), encompassing seamless transition to CMC (Chemistry, Manufacturing, and Controls) and downstream process development. Designed to revolutionize and expedite the biologics discovery process, these platforms support the development of novel therapeutic candidates through advanced biotechnological innovations.
• Consultation Services in relation to Biopharmaceutical Technology: WuXi Biologics delivers expert consultation services, offering guidance and advice on the complexities of biopharmaceutical technology to clients navigating the biologics industry landscape.
• International Sales Contracting Services: The company extends its prowess to international sales contracting services, fostering global partnerships and facilitating the international distribution and commercialization of biologic products.
• Testing and Development of Testing Technologies: With a commitment to ensuring the highest standards of quality and safety, WuXi provides testing and development of innovative testing technologies, crucial for the successful development and manufacturing of biologics.
• Sales and Marketing Services: Beyond the technical aspects of biologics development and manufacturing, WuXi Biologics offers sales and marketing services, assisting in the promotion and commercial success of biologic products.
• Production and Sales of Medicals, and Biologics Clinical and Manufacturing Services: The company is involved in the production and sales of medical products, in addition to offering comprehensive biologics clinical and manufacturing services, encompassing the full spectrum of biologics production from the laboratory bench to the manufacturing floor.
• Vaccine CDMO and Related Business: WuXi Biologics delves into the vaccine sector through contract development and manufacturing organization (CDMO) services, addressing the growing demand for vaccine development and production.
• Research Service Agreement with BioNTech SE: A testament to its collaborative spirit and capability, WuXi Biologics has entered into a research service agreement with BioNTech SE, aiming to discover and investigate monoclonal antibodies for the creation of next-generation therapeutic product candidates.